Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

upm din borisov sad - pentoxifyllinum - solutie injectabila - 20 mg/ml

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

arena group s.a. - romania - ciprofloxacinum - compr. film. - 100mg - chinolone antibacteriene fluorochinolone

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

arena group s.a. - romania - ciprofloxacinum - compr. film. - 250mg - chinolone antibacteriene fluorochinolone

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

arena group s.a. - romania - ciprofloxacinum - compr. film. - 500mg - chinolone antibacteriene fluorochinolone

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

arena group s.a. - romania - ciprofloxacinum - compr. film. - 750mg - chinolone antibacteriene fluorochinolone

Uniunea Europeană - română - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Uniunea Europeană - română - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinurie, paroxismal - imunosupresoare - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

berlin-chemie ag (menarini group) - o combinatie - solutie perfuzabila - 100 mg/ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

berlin-chemie ag (menarini group) - o combinatie - solutie perfuzabila - 100 mg/ml

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

fresenius kabi austria gmbh - austria - combinatii - sol. perf. - 100g/l - solutii pentru administrare intravenoasa solutii pentru nutritie parenterala